The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis

• Published in: Nutrition (Burbank, Los Angeles County, Calif.) Los Angeles County, Calif.), 1996-05, Vol.12 (5), p.334-339
• Main Authors: Katz, David P., Manner, Tuula, Furst, Peter, Askanazi, Jeffrey
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Biological and medical sciences; Child; cystic fibrosis; Cystic Fibrosis - physiopathology; Cystic Fibrosis - therapy; Double-Blind Method; Fat Emulsions, Intravenous - administration & dosage; Fat Emulsions, Intravenous - therapeutic use; Fatty Acids, Nonesterified - blood; Fatty Acids, Nonesterified - classification; Fatty Acids, Nonesterified - metabolism; Fatty Acids, Omega-3 - administration & dosage; Fatty Acids, Omega-3 - therapeutic use; Female; fish oils; Fish Oils - administration & dosage; Fish Oils - chemistry; Fish Oils - therapeutic use; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Infusions, Intravenous; intravenous lipid emulsions; Liver Function Tests; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Other diseases. Semiology; Parenteral Nutrition, Total; Patient Selection; Respiratory Function Tests; Safety; Time Factors
• ISSN: 0899-9007; 1873-1244
• DOI: 10.1016/S0899-9007(96)80056-6

The effects of parenteral nutrition supplemented with a lipid emulsion enriched with the omega-3 fatty acids (FA), eicosapentaenoate (20:5n-3) and docosahexaenoate (22:6n-3), derived from fish oil were compared to a standard lipid emulsion containing omega-6 FA in patients with cystic fibrosis (CF). Patients were randomized to receive either Omegavenous 10%, which contains fish oil (IFO), or Liposyn III 10% (control) daily for 1 mo at a dose of 150 mg/kg. There were no observed allergic or toxic reactions, no abnormalities in liver function tests or coagulation parameters. To assess the bioavailability of the lipid administered, measurement of plasma free fatty acid (FFA) levels were made of the essential FA. There were no adverse changes in plasma levels of the omega-6 FA (18:2n-6, 18:3n-6, 20:3n-6, and 20:4n-6), and plasma levels of the omega-3 FA (20:5n-3 and 22:6n-3) increased significantly during the 1-mo study. There were no significant changes in plasma FFA profiles of the essential FA for the patients receiving the control lipid. The effect of treatment on pulmonary function was also investigated. There were no significant changes in FVC, FEV 1, PEFR, FEV 1/FVC, or FEF 25–75 (absolute value or percentage) over the 4 weeks of study in the group receiving IFO or control. This preliminary investigation suggests that intravenous administration of fish oils enriched with long chain omega-3 FA to patients with CF is safe and bioavailable.